Clinical Trial Detail

NCT ID NCT02315066
Title Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pfizer
Indications

hepatocellular carcinoma

melanoma

bladder urothelial carcinoma

stomach cancer

clear cell renal cell carcinoma

lung non-small cell carcinoma

cervix carcinoma

head and neck squamous cell carcinoma

Therapies

PF-04518600

PF-04518600 + Utomilumab

Age Groups: adult

No variant requirements are available.